Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selinexor in Combination With Chemotherapy to Treat Relapsed/Refractory Multiple Myeloma Patients

Next Previous
Trial Profile

Selinexor in Combination With Chemotherapy to Treat Relapsed/Refractory Multiple Myeloma Patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Doxorubicin liposomal (Primary) ; Selinexor (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use

Most Recent Events

  • 12 Dec 2023 Interim Results (n= As of July 26, 2023, n=44) assessing safety and efficacy of of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 15 Jun 2023 Results safety analysis (n=14; as of data cutoff: 11 Feb 2023) presented at the 28th Congress of the European Haematology Association
  • 15 Jun 2023 Results of interim analysis (As of Feb 24th 2023, n=28) assessing the preliminary efficacy, safety, and tolerability of the combination of Xd plus chemotherapy drugs in pts with RRMM presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top